Predictors of left ventricular reverse remodeling after percutaneous therapy for mitral regurgitation with the MitraClip system
- PMID: 32104977
- DOI: 10.1002/ccd.28779
Predictors of left ventricular reverse remodeling after percutaneous therapy for mitral regurgitation with the MitraClip system
Abstract
Objectives: To investigate the predictors and clinical impact of left ventricular reverse remodeling (LVRR) after MitraClip (MC) therapy for degenerative (DMR) and functional mitral regurgitation (FMR).
Background: MC therapy induces LVRR in patients with mitral regurgitation (MR) at high-risk for surgery. However, specific data on predictors of LVRR therapy are limited.
Methods: This study included 164 patients treated by MC implantation with complete clinical and echocardiographic evaluation at baseline, 6 months, and 12 months. LVRR was defined as a decrease of ≥10% of the left ventricular end-diastolic diameter after 12 months and was found in 49% of the patients.
Results: LVRR was associated with significantly reduced event rate 2 years after MC procedure. In the total cohort, multivariate regression analysis determined severe recurrent/residual MR after 12 months (p = .010, odds ratio [OR] = 0.26), male gender (p = .050, OR = 0.49) and left ventricular ejection fraction (LVEF) <20% (p = .046, OR = 0.24) as predictors of absence of LVRR. In the subgroup analysis according to etiology of MR, multivariate regression analysis revealed severe recurrent/residual MR after 12 months (p = .04, OR = 0.184) to inversely predict LVRR only in the DMR subgroup. In FMR, residual severe tricuspid regurgitation (TR) inversely predicts LVRR (p = .032, OR = 0.361).
Conclusions: LVRR occurs in half of the patients after MC and is associated with reduced MACCE rates at follow-up. Combined information on residual/recurrent MR, baseline LVEF and gender predict LVRR after MC procedure. While residual/recurrent MR is the independent predictor for the absence of LVRR in DMR, in FMR only severe residual TR independently predict LVRR.
Keywords: edge-to-edge repair; left ventricle; mitral valve; recurrent mitral regurgitation; reverse remodeling; tricuspid regurgitation.
© 2020 The Authors. Catheterization and Cardiovascular Interventions published by Wiley Periodicals, Inc.
Comment in
-
Predicting who benefits from mitral valve percutaneous repair: It's not just the valve.Catheter Cardiovasc Interv. 2020 Sep 1;96(3):698. doi: 10.1002/ccd.29212. Catheter Cardiovasc Interv. 2020. PMID: 32935948 No abstract available.
References
REFERENCES
-
- Grayburn PA, Foster E, Sangli C, et al. Relationship between the magnitude of reduction in mitral regurgitation severity and left ventricular and left atrial reverse remodeling after MitraClip therapy. Circulation. 2013;128(15):1667-1674.
-
- Herbrand T, Eschenhagen S, Zeus T, et al. Acute reverse annular remodeling during MitraClip therapy predicts improved clinical outcome in heart failure patients: a 3D echocardiography study. Eur J Med Res. 2017;22(1):33.
-
- Schrage B, Kalbacher D, Schwarzl M, et al. Distinct hemodynamic changes after interventional mitral valve edge-to-edge repair in different phenotypes of heart failure: an integrated hemodynamic analysis. J Am Heart Assoc. 2018;7(6):e007963.
-
- Feldman T, Wasserman HS, Herrmann HC, et al. Percutaneous mitral valve repair using the edge-to-edge technique: six-month results of the EVEREST Phase I Clinical Trial. J Am Coll Cardiol. 2005;46(11):2134-2140.
-
- Giannini C, Petronio AS, De Carlo M, et al. Integrated reverse left and right ventricular remodelling after MitraClip implantation in functional mitral regurgitation: an echocardiographic study. Eur Heart J Cardiovasc Imaging. 2014;15(1):95-103.
MeSH terms
LinkOut - more resources
Full Text Sources